Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-844203
CT-322 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322 |
| Arm 2 | ACTIVE_COMPARATOR | Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution) |
| Name | Type | Description |
|---|---|---|
| Irinotecan | DRUG | Solution, IV, 180 mg/m2, Q14 days, Until PD |
| 5-Fluorouracil (bolus) | DRUG | Solution, IV, 400 mg/m2, Q14 days, Until PD |
| 5-Fluorouracil (infusional) | DRUG | Solution, IV, 2400 mg/m2, Q14 days, Until PD |
| Leucovorin calcium | DRUG | Solution, IV, 400 mg/m2, Q14 days, Until PD |
| CT-322 | DRUG | Solution, IV, 2 mg/kg, Q7 days, Until PD |
| Bevacizumab | DRUG | Solutions, IV, 5 mg/kg, Q14 days, Until PD |
| Bevacizumab Placebo (saline solution) | DRUG | Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD |
Inclusion Criteria: * ECOG Performance Status (PS) ≤1 * Histologically or cytologically confirmed, unresectable metastatic colorectal cancer * Measurable disease by RECIST guidelines * Evidence of disease progression following first-line therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab...
Top 20 of 80 competitors
CT-322 is an investigational oncology drug studied in cancer, including advanced solid tumors, non-Hodgkin's lymphoma, and metastatic colorectal cancer. It was evaluated as a single agent and in combination with chemotherapy for second-line treatment of metastatic colorectal cancer. It is not an approved therapy.
CT-322 was developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the clinical research program for the drug in oncology indications.
CT-322 is in Phase 1 development. It is an investigational agent and has not been approved for any indication. A Phase 1 study in advanced solid tumors and non-Hodgkin's lymphoma has been completed, and a Phase 2 study in metastatic colorectal cancer has also been completed.
CT-322 has been studied in two completed trials. NCT00374179 was a Phase 1 trial in advanced solid tumors and non-Hodgkin's lymphoma with 40 patients. NCT00851045 was a Phase 2 trial combining CT-322 with chemotherapy for second-line metastatic colorectal cancer with 17 patients.
No. CT-322 is an investigational drug and is not FDA approved. It remains in clinical development, with completed Phase 1 and Phase 2 trials in cancer and metastatic colorectal cancer.